Rep. Maria Elvira Salazar Purchases Shares of Biogen Inc. (NASDAQ:BIIB)

Posted by Linda Flegge on Jun 11th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $50,001 and $100,000 in Biogen stock on May 11th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/12/2026.
Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.
Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.

Biogen Price Performance

Shares of Biogen stock opened at $194.24 on Thursday. The business has a 50 day simple moving average of $188.07 and a two-hundred day simple moving average of $184.03. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97. The stock has a market capitalization of $28.68 billion, a P/E ratio of 20.84 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB – Get Free Report) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts predict that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BIIB shares. Evercore started coverage on Biogen in a report on Friday, May 15th. They set an “outperform” rating for the company. Piper Sandler reissued an “overweight” rating and set a $225.00 target price (up from $214.00) on shares of Biogen in a report on Friday, May 15th. Wedbush increased their target price on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. HSBC increased their target price on Biogen from $143.00 to $150.00 and gave the company a “reduce” rating in a report on Tuesday, March 17th. Finally, Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $217.26.

View Our Latest Analysis on BIIB

Institutional Investors Weigh In On Biogen

A number of large investors have recently made changes to their positions in the stock. Rothschild Investment LLC grew its position in shares of Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares in the last quarter. Meeder Advisory Services Inc. grew its position in shares of Biogen by 1.2% in the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock valued at $866,000 after purchasing an additional 57 shares in the last quarter. Kera Capital Partners Inc. grew its position in shares of Biogen by 3.5% in the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 58 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Biogen by 1.5% in the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after purchasing an additional 65 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its position in Biogen by 24.4% in the fourth quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 66 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Key Biogen News

Here are the key news stories impacting Biogen this week:

Positive Sentiment: Needham upgraded Biogen to Buy and set a $255 price target, citing a stronger outlook for the commercial portfolio and multiple Phase 3 readouts through 2029, including potential upside from Leqembi and recently acquired products. Article Title
Positive Sentiment: At Biogen’s 2026 annual meeting, shareholders backed the board, auditor, and pay policies, which suggests governance support and no major shareholder revolt. Article Title
Neutral Sentiment: Commentary comparing Biogen with other biotech stocks says the company has recently outperformed peers and analysts remain reasonably upbeat, reinforcing a stable sentiment backdrop rather than a new catalyst. Article Title
Negative Sentiment: The Schall Law Firm announced a securities-law investigation into whether Biogen made false or misleading statements or omitted material information, adding headline risk and potential litigation overhang. Article Title
Negative Sentiment: Pomerantz LLP also launched an investor investigation into Biogen, reinforcing concerns that the stock could face legal scrutiny and additional uncertainty. Article Title

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

(Get Free Report)

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.